StockNews.com assumed coverage on shares of Prothena ( NASDAQ:PRTA – Get Rating ) in a report issued on Thursday morning. The brokerage issued a hold rating on the biotechnology company's stock. PRTA has been the subject of several other reports. Citigroup lowered their price target on Prothena from $76.00 to $72.00 and set a buy rating for the company in a research report on Monday, February 27th. HC Wainwright lifted their target price on Prothena from $75.00 to $90.00 in a report on Friday, May 5th.

https://www.dailypolitical.com/2023/05/21/prothena-nasdaqprta-earns-hold-rating-from-analysts-at-stocknews-com.html

#dailypolitical